PATENT CLAIM ANALYSIS

Application Number: 15875657
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "170000"]

Abstract:
A hormone modulator for causing cellular apoptosis in triple-negative breast cancer cells. The hormone modulator includes at least one of Δ5-androsten-3β,17β-diol and Δ5-androsten-3β,7β,17β-triol and estradiol.

Claim (Index 14):
The method of  claim 9 , wherein the treatment is administered, in vitro, to the triple-negative breast cancer cells.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 86.0
- Lexical Diversity: 1.17391
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14798208', '14774163', '10390032', '14293632', '14645578']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7282096447910212
- 35 USC 102 Novelty (BERT): 0.4938005310140774
- Combined Prediction Score: 0.7047687334133268
- Mean Citation Score: 135.915908
- Max Citation Score: 141.99796
- Similarity Product: 85.4378292005682

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test